- Home
- ZLAB vs RCKT Comparison
ZLAB vs RCKT Comparison
Compare ZLAB & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZLAB | RCKT |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 340.9M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZLAB | RCKT |
|---|---|---|
| Price | $18.34 | $3.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $57.22 | $29.12 |
| AVG Volume (30 Days) | 937.7K | ★ 2.0M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $441,629,000.00 | N/A |
| Revenue This Year | $26.16 | N/A |
| Revenue Next Year | $30.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.14 | N/A |
| 52 Week Low | $16.82 | $2.19 |
| 52 Week High | $44.34 | $13.35 |
Technical Indicators
Market Signals| Indicator | ZLAB | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 40.35 | 55.01 |
| Support Level | $17.37 | $3.19 |
| Resistance Level | $19.01 | $3.60 |
| Average True Range (ATR) | 0.63 | 0.19 |
| MACD | 0.31 | 0.02 |
| Stochastic Oscillator | 57.51 | 70.65 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.